Abstract |
Choice of calcineurin inhibitor may be a contributing factor to deteriorating patient and graft survival following liver transplantation for hepatitis C virus (HCV). In our multicenter, open-label LIS2T study, de novo liver transplant patients stratified by HCV status were randomized to cyclosporine or tacrolimus. Follow-up data were obtained in an observational study of 95 patients. Mean follow-up was 34 and 37 months, respectively, for cyclosporine-treated (n = 47) and tacrolimus-treated (n = 48) patients. In patients not receiving antiviral therapy, 22 of 31 given cyclosporine (72%) and 24 of 29 given tacrolimus (83%) had biochemical recurrence of HCV. In 68 patients with at least one biopsy, histological evidence of HCV-related hepatitis was present in 27 of 31 (87%) cyclosporine-treated patients and 37 of 37 (100%) tacrolimus-treated patients (P = .02, chi-square test). Three-year actuarial risk of fibrosis stage 2 was 66% with cyclosporine and 90% with tacrolimus; for fibrosis stage 3 or 4 it was 46% and 80%, respectively. Three graft losses were attributed to HCV recurrence in cyclosporine-treated patients and six in tacrolimus-treated patients. Tacrolimus may be associated with increased risk of histological HCV disease recurrence compared to cyclosporine.
|
Authors | F Villamil, G Levy, G L Grazi, S Mies, D Samuel, F Sanjuan, M Rossi, J Lake, S Munn, F Mühlbacher, L Leonardi, U Cillo |
Journal | Transplantation proceedings
(Transplant Proc)
Vol. 38
Issue 9
Pg. 2964-7
(Nov 2006)
ISSN: 0041-1345 [Print] United States |
PMID | 17112875
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Chemical References |
- Immunosuppressive Agents
- Cyclosporine
- Tacrolimus
|
Topics |
- Adult
- Carcinoma, Hepatocellular
(surgery)
- Cyclosporine
(therapeutic use)
- Female
- Follow-Up Studies
- Hepatitis C
(epidemiology, surgery)
- Humans
- Immunosuppressive Agents
(therapeutic use)
- Liver Neoplasms
(surgery)
- Liver Transplantation
(immunology, physiology)
- Male
- Middle Aged
- Recurrence
- Risk Factors
- Tacrolimus
(therapeutic use)
- Time Factors
- Treatment Outcome
|